Giorgio Vittorio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses challenges in the use of personalized medicines for lung cancers, which have greatly improved overall survival. Prof. Scagliotti explains that the plasticity of tumor cells enables them to acquire resistance to targeted immunotherapy, and how this may be addressed in the future using molecules targeting this resistance mechanism. This video was recorded at the European Lung Cancer Congress (ELCC), held in Geneva, Switzerland.